J&J's depression drug Spravato wins European panel vote

(Reuters) - Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body said on Friday.The treatment, Spravato, which is the chemical mirror image of the often-abused anesthetic ketamine, won U.S. approval in March, making it the first new type of drug for depression in more than 30 years. However, due to the potential for abuse, Spravato was approved with a host of restrictions that included requiring the drug..